Weight-of-Evidence Submissions: How Modeled and Empirical Data Combine in a PMTA

Answers: “weight of evidence PMTA modeled empirical”

FDA does not evaluate a PMTA on a single study. It weighs the totality — a "weight-of-evidence" approach. Understanding this is what keeps modeled evidence in its proper, powerful place: it strengthens the file without pretending to replace confirmatory work.

How the pieces fit

• Modeled evidence (ELCR, in-silico PK, PHIA) — fast, cheap, ideal for screening and for filling early quantitative gaps.
• Empirical evidence (lab HPHC, confirmatory clinical studies) — slower, costlier, but confirmatory.
• The synthesis — a §1114.7 file that presents both, consistently, with 14–21 citations, so each claim is sourced and internally coherent.

The strategic point: use modeling to decide what to file and to draft the evidence spine, then commit empirical spend only on the formula that survived screening.

Pros vs. cons. Pro: sequencing modeling first cuts wasted confirmatory spend and produces a coherent narrative. Con: over-reliance on modeling without confirmatory data weakens substantive review — balance is the whole point.

Who should NOT buy: applicants whose strategy is purely empirical and who don't want a modeling layer.